Kaoru Takasaki

Kaoru Takasaki

Auto-generated profile, based on publicly available information

Kaoru Takasaki

Division of Hematology Children's Hospital of Philadelphia Philadelphia PA USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
KTKaoru Takasaki
Kaoru Takasaki
DFDavid F. Friedman
David F. Friedman
SUStacey Uter
Stacey Uter
SVSunitha Vege
Sunitha Vege
CWConnie M. Westhoff
Connie M. Westhoff
SCStella T. Chou
Stella T. Chou

1 September 2016 in Pediatric Neurology
Verified
Journal Article
Closed access
KTKaoru Takasaki
Kaoru Takasaki
ASAndrea Diaz Stransky
Andrea Diaz Stransky
GMGeoffrey Miller
Geoffrey Miller

31 October 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
YSYing Ting Sit
Ying Ting Sit
KTKaoru Takasaki
Kaoru Takasaki
HAHyun Hyung An
Hyun Hyung An
YXYan Xiao
Yan Xiao
CHChristian Hurtz
Christian Hurtz
SCStella T. Chou
Stella T. Chou
Patients with Down syndrome (DS), or trisomy 21 (T21), are at increased risk of transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (ML-DS). Both TAM and ML-DS require prenatal somatic mutations in GATA1 , resulting in the truncated isoform GATA1s. The mechanism by which individual chromosome 21 (HSA21) genes synergize with GATA1s for leukemic transformation is challenging to study, in part due to limited human cell models with wild-type GATA1 (wtGATA1) or GATA1s. HSA21-encoded DYRK1A is overexpressed in ML-DS and may be a therapeutic target. To determine how DYRK1A influences hematopoiesis in concert with GATA1s, we used gene editing to disrupt all 3 alleles of DYRK1A in isogenic T21 induced pluripotent stem cells (iPSCs) with and without the GATA1s mutation. Unexpectedly, hematopoietic differentiation revealed that DYRK1A loss combined with GATA1s leads to increased megakaryocyte proliferation and decreased maturation. This proliferative phenotype was associated with upregulation of D-type cyclins and hyperphosphorylation of Rb to allow E2F release and derepression of its downstream targets. Notably, DYRK1A loss had no effect in T21 iPSCs or megakaryocytes with wtGATA1. These surprising results suggest that DYRK1A and GATA1 may synergistically restrain megakaryocyte proliferation in T21 and that DYRK1A inhibition may not be a therapeutic option for GATA1s-associated leukemias.

22 November 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
KTKaoru Takasaki
Kaoru Takasaki
DHDavid Hehir
David Hehir
LRLeslie Raffini
Leslie Raffini
BSBen Samelson-Jones
Ben Samelson-Jones
ESEvelyn Shih
Evelyn Shih
ADAleksandra Sarah Dain
Aleksandra Sarah Dain
Click on the article title to read more.

15 April 2023 in Stem Cell Research
Verified
Journal Article
Open access
KTKaoru Takasaki
Kaoru Takasaki
SKSara S. Kumar
Sara S. Kumar
AGAlyssa Gagne
Alyssa Gagne
DFDeborah L. French
Deborah L. French
SCStella T. Chou
Stella T. Chou
Trisomy 21 (T21), or Down Syndrome (DS), is a common chromosomal disorder resulting from a third copy of chromosome 21 (HSA21). Transient myeloproliferative disorder (TMD) is a pre-leukemic condition that occurs only in neonates with DS and is characterized by a mutation in the transcription factor GATA1 that results in a truncated protein (GATA1s). We generated a pair of isogenic T21 lines derived from a patient with TMD that differ only in GATA1 status. The iPSC lines were characterized for pluripotency, differentiation potential, and genomic stability. These lines are a valuable resource for studying T21 hematopoietic diseases.

17 July 2025 in Stem Cell Reports
Verified
Journal Article
Open access
KTKaoru Takasaki
Kaoru Takasaki
EWEric K. Wafula
Eric K. Wafula
JFJian Meng Fan
Jian Meng Fan
YSYing Ting Sit
Ying Ting Sit
SKSara S. Kumar
Sara S. Kumar
SCStella T. Chou
Stella T. Chou
Trisomy 21 (T21) is associated with baseline erythrocytosis, thrombocytopenia, neutrophilia, transient abnormal myelopoiesis (TAM), and myeloid leukemia of Down syndrome (ML-DS). TAM and ML-DS blasts harbor mutations in GATA1, resulting in the exclusive expression of the truncated isoform GATA1s. Germline GATA1s mutations in individuals without T21 cause congenital cytopenias, typically without a leukemic predisposition. To dissect the developmental effects of T21 and GATA1s, we used a combination of isogenic human induced pluripotent stem cells, primary human fetal and neonatal cells, and single-cell transcriptomics to interrogate hematopoietic progenitors differing only by chromosome 21 and/or GATA1 status. Both T21 and GATA1s induced early lineage skewing, and trajectory analysis revealed that GATA1s altered the temporal regulation of lineage-specific transcriptional programs, disrupting cell proliferation and maturation irrespective of chromosomal context. These studies uncovered unexpected heterogeneity and lineage priming in early, multipotent hematopoietic progenitors and identified transcriptional and functional maturation blocks linked to GATA1s.